Viatris, a global healthcare company, has acquired Aculys Pharma, a Japan-based biopharmaceutical company specializing in neurological and psychiatric disorders, for an undisclosed amount. This corporate acquisition marks a strategic expansion for Viatris, integrating Aculys Pharma's focused expertise and pipeline into its broader operations.
Aculys Pharma operates with the mission "Catalyst to Access," aiming to bridge the gap to innovative medical care in Japan. The company focuses on addressing unmet medical needs in neurological and psychiatric diseases by introducing and developing superior medicines from Western countries for the Japanese market, thereby tackling issues of drug lag and loss. Beyond product development, Aculys Pharma is committed to enhancing the entire patient experience, from awareness and diagnosis to treatment and resolving related social challenges, often through cross-sectional partnerships and new technologies. Its pipeline includes innovative treatments like Spidia Nasal Spray for epileptic seizures, which recently received manufacturing and marketing approval.
The acquisition is strategically significant for Viatris, allowing it to strengthen its presence and portfolio in the specialized and high-unmet-need area of neurological and psychiatric diseases, particularly within the Japanese market. Viatris is expected to leverage Aculys Pharma's deep understanding of the local healthcare landscape and regulatory environment, as well as its established connections for introducing and commercializing advanced therapies. This move aligns with Viatris's broader objective of providing access to medicines globally by incorporating Aculys Pharma's targeted approach and innovative solutions.
Expected synergies include the accelerated development and broader commercial reach for Aculys Pharma's existing and future products through Viatris's global infrastructure and resources. The combined entity is anticipated to enhance the availability of innovative treatments for patients facing neurological and psychiatric conditions in Japan, bringing together Aculys Pharma's focused expertise with Viatris's extensive operational capabilities.